title: [Interleukin 2 revival: a revisited model and new therapeutic applications].
abstract: Interleukin-2, a cytokine identified as T-cell growth factor, has long been regarded as central to the development and effector activities of immune responses. Several gene knockout mouse studies and observations in humans, however, have undermined that vision, and the discovery of regulatory T cells showed that IL-2, in contrast to the accepted dogma, has the essential function of promoting (1) homeostasis and (2) the function of these T regulator cells the which, limit the action of the effector cells, in particular to prevent the autoimmune reaction drifts. This new paradigm has major implications on the use of IL-2 in therapy, and creates new strategies to manipulate the Teffectors/Tregulators balance.
authors.affiliation: Centre de recherche en cancérologie Nantes-Angers (CRCNA), UMR Inserm 892 - CNRS 6299, Université de Nantes, IRS-UN, 8, quai Moncousu, BP70721, F-44007, Nantes, France.
authors.forename: Yannick
authors.initials: Y
authors.lastname: Jacques
authors.affiliation: Centre de recherche en cancérologie Nantes-Angers (CRCNA), UMR Inserm 892 - CNRS 6299, Université de Nantes, IRS-UN, 8, quai Moncousu, BP70721, F-44007, Nantes, France.
authors.forename: Erwan
authors.initials: E
authors.lastname: Mortier
mesh_terms: D000818:Animals; D001327:Autoimmune Diseases / Q000188:drug therapy / Q000276:immunology / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D006706:Homeostasis; D006801:Humans; D007249:Inflammation / Q000276:immunology / Q000378:metabolism; D007376:Interleukin-2 / Q000502:physiology* / Q000627:therapeutic use; D008954:Models, Biological; D009369:Neoplasms / Q000188:drug therapy / Q000276:immunology; D050378:T-Lymphocytes, Regulatory / Q000276:immunology / Q000378:metabolism; D035703:Therapies, Investigational / Q000379:methods*
chemical_list: D007376:Interleukin-2